BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25573098)

  • 61. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S; Takabe K; Suzuki K
    Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
    Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
    Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
    BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer].
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Shen-Tu JZ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):540-6. PubMed ID: 23086647
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
    Wu GQ; Liu NN; Xue XL; Cai LT; Zhang C; Qu QR; Yan XJ
    Asian Pac J Cancer Prev; 2014; 15(10):4153-8. PubMed ID: 24935362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
    Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
    Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
    Ke HG; Zhou XY; Shen Y; You QS; Yan Y; Shen ZY
    Oncol Res; 2012; 20(5-6):221-9. PubMed ID: 23581229
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
    Podmaniczky E; Fábián K; Pápay J; Puskás R; Gyulai M; Furák J; Tiszlavicz L; Losonczy G; Tímár J; Moldvay J
    Pathol Oncol Res; 2015 Apr; 21(2):423-31. PubMed ID: 25194563
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
    PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
    Huang ZL; Cao X; Luo RZ; Chen YF; Zhu LC; Wen Z
    Oncol Lett; 2016 Jan; 11(1):299-305. PubMed ID: 26870207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
    He YW; Zhao ML; Yang XY; Zeng J; Deng QH; He JX
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):861-7. PubMed ID: 25732635
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.